瑞舒伐他汀对持续性心房颤动导管消融术后早期复发的影响

Evaluation of rosuvastatin in preventing early recurrence of persistent atrial fibrillation after catheter ablation treatment

目的探讨瑞舒伐他汀对消融术后早期炎性反应及术后早期复发的影响。方法连续入选84例拟行导管消融术的持续性心房颤动(房颤)患者,随机分为两组:A组42例给予瑞舒伐他汀10 mg/d;B组42例为空白对照组。随访术后1个月患者的血脂水平、血清高敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)以及患者消融术后1个月内的复发率。比较消融术前、术后以及两组间炎性指标变化及其与术后早期复发的关系。结果消融术后1个月时,A组的hs-CRP及IL-6水平显著低于B组,且明显低于治疗前;而B组hs-CRP及IL-6水平较术前显著增高。术后1个月,A组和B组分别有29例和25例患者成功维持窦性心律(P=0.362);进一步将A组分为未复发组和复发组,未复发组的炎性指标降低幅度较大,但差异无统计学意义。结论消融术后早期存在显著的炎性反应。瑞舒伐他汀虽能有效降低炎性反应,但仅有减少术后早期复发的趋势。炎症指标降低越多房颤复发率越低,但差异无统计学意义。

Objective To investigate the value of rosuvastatin in alleviating early inflammatory reaction and in preventing early recurrence of persistent atrial fibrillation （AF） after catheter ablation treatment. Methods A total of 84 patients with persistent AF who had received catheter ablation were enrolled in this study. The patients were randomly and equally divided into group A （n = 42, study group） and group B （n = 42, control group）. Rosuvastatin therapy （10 mg/d, 42 patients） was employed in the patients of group A, while no medication was used in the patients of group B. One month after the ablation treatment, the serum lipid level, hs-CRP and IL-6, as well as the recurrence rate of all kinds of arrhythmia were determined. The preoperative and postoperative levels of inflammatory markers were also determined, the results were compared between the two groups, and its correlation with the early recurrence of AF was evaluated. Results One month after the ablation treatment, the levels of inflammatory markers, including hs-CRP and IL-6, in the study group were significantly lower than those in the control group, as well as lower than those determined before treatment, while in the control group the serum hs-CRP and IL-6 levels became significantly higher than the preoperative ones. Sinus rhythm was successfully maintained in 29 cases （69%） of the study group and in 25 cases （59.5%） of the control group, while the difference was not statistically significant （P = 0.362）. The patients of the study group were further divided into non-recurrence sub-group （n = 29） and recurrence sub-group （n = 13）. The reduction in inflammatory marker level in the non-recurrence sub-group was greater than that in the recurrence sub-group although the difference was not statistically significant. Conclusion There is remarkable inflammatory reactions during the early period after catheter ablation. Rosuvastatin can effectively relieve the degree of inflammatory reaction, although it has only a slight effect in reducing the early recurrence rate after catheter ablation of AF. The greater the inflammatory markers levels are reduced, the lower the recurrence rate of AF will be, although the difference is not statistically significant.